Abstract

Breast cancer is a multifactorial disease. A spectrum of internal and external factors contributes to the disease promotion such as a genetic predisposition, chronic inflammatory processes, exposure to toxic compounds, abundant stress factors, a shift-worker job, etc. The cumulative effects lead to high incidence of breast cancer in populations worldwide. Breast cancer in the USA is currently registered with the highest incidence rates amongst all cancer related patient cohorts. Currently applied diagnostic approaches are frequently unable to recognise early stages in tumour development that impairs individual outcomes. Early diagnosis has been demonstrated to be highly beneficial for significantly enhanced therapy efficacy and possibly full recovery. Actual paper shows that the elaboration of an integrative diagnostic approach combining several levels of examinations creates a robust platform for the reliable risk assessment, targeted preventive measures and more effective treatments tailored to the person in the overall task of breast cancer management. The levels of examinations are proposed, and innovative technological approaches are described in the paper. The absolute necessity to create individual patient profiles and extended medical records is justified for the utilising by routine medical services. Expert recommendations are provided to promote further developments in the field.

Highlights

  • Breast cancer is the most common cause of cancerrelated death among women in the USA, the highest cancer related incidence rates are currently registered for the breast cancer patient cohorts [2] – see Figure 1A

  • Breast Cancer Metastatic Disease (BCMD) is currently incurable: challenges of diagnostics and treatment Breast Cancer Metastatic Disease (BCMD) Diagnostic approaches routinely applied in medical practice are frequently unable to recognise early stages in breast cancer development that impair the outcome

  • It is estimated that about 6% of breast cancer patients demonstrate a clinical picture of metastatic disease already at the time of diagnosis

Read more

Summary

Open Access

Disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?. Olga Golubnitschaja1,2*, Kristina Yeghiazaryan, Vincenzo Costigliola, Daniela Trog, Michael Braun, Manuel Debald, Walther Kuhn and Hans H Schild

Clinical development
Blood metabolomics for quantification of disease relevant metabolite patterns
Spot number Access Accession name Protein name number
Profile alterations versus controls
Nucleotide metabolism
Findings
Membrane architecture and signalling protein similar
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call